



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Susanna A. Alami et al.	) Confirmation No. 3007
Application No.: 10/516,423	) Group Art Unit: 1615
Filed: July 25, 2005	Examiner: Thurman K. Page
For: Immediate Release Pharmaceutical Formulation	)
Commissioner for Patents U.S. Patent and Trademark Office	Date: May 9, 2007
Customer Window, Mail Stop Amendment Randolph Building 401 Dulany Street	•
Alexandria, VA 22314	

## Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request that the Examiner consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. patents and published applications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

Further, the Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No.	U.S. Patent No.	PCT Publication No.
	Filing Date	Issue Date	PCT Publication Date
Inghardt et al.	10/432,411	7,129,233	WO 02/44145
	May 21, 2003	October 31, 2006	June 6, 2002
Inghardt et al.	10/487,805	7,056,907	WO 03/018551
	February 26, 2004	June 6, 2006	March 06, 2003
Magnusson et al.	10/516,420		WO 03/101424
	November 29, 2004		December 11, 2003
Ahlqvist et al.	10/516,422		WO 03/101957
	May 20, 2005	1	December 11, 2003
Inghardt et al.	11/520,052		WO 02/44145
	September 13, 2006		June 6, 2002
Inghardt et al.	11/520,063		WO 02/44145
	September 13, 2006		June 6, 2002

A copy of the specification and claims for each of the above-listed applications, in the form of the published PCT application from which such application was filed is being submitted herewith.

Consideration of each listed application is earnestly solicited.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Page 3

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: May 9, 2007 Morgan Lewis & Bockius LLP

Customer No. 09629 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000 By:

Registration No. 46,882

Tel. No.: (202) 739-5915 Fax No.: (202) 739-3001

# Attorney Docket No. Application No. 056291-5273 10/516,423

(Use several sheets if necessary)

MAY 0 9 2007

Applicants: Susanna A. Alami et al.

Filing Date: July 25, 2005

Group Art Unit: 1615

PTO Form 1449 May 9, 2007

U.S. PATENT DOCUMENTS

Initial		Document No. Date Name		Name	Class	Sub-Class	Filing Date
1 /	v.C)/-	4,346,078	August 24, 1982	Bajusz et al.			
Т	2.	5,498,724	March 12, 1996	Nystrom et al.			
	3.	5,559,232	September 24, 1996	Ackermann et al.			
	4.	5,602,253	February 11, 1997	Antonsson et al.			
	5.	5,659,071	August 19, 1997	Nystrom et al.			
	6.	5,705,487	January 6, 1998	Schacht et al.			
	7.	5,707,966	January 13, 1998	Schacht et al.			
Т	8.	5,710,130	January 20, 1998	Schacht et al.			
1	9.	5,723,444	March 3, 1998	Antonsson et al.			
Т	10.	5,744,487	April 28, 1998	Ohshima et al.			
T	11.	5,780,631	July 14, 1998	Antonsson et al.			
	12.	5,783,563	July 21, 1998	Antonsson et al.			
	13.	4,792,452	December 20, 1998	Howard et al.			
Т	14.	5,856,307	January 5, 1999	Antonsson et al.			
Т	15.	5,939,392	August 17, 1999	Antonsson et al.			
	16.	5,965,692	October 12, 1999	Gustafsson et al.			
	17.	6,030,972	February 29, 2000	Bohm et al.			
	18.	6,051,568	April 18, 2000	Gustafsson et al.			
	19.	6,221,898	April 24, 2001	Antonsson			
	20.	6,225,287	May 1, 2001	Edvardsson et al.			
Т	21.	6,255,301	July 3, 2001	Gustafsson et al.			
	22.	6,262,028	July 17, 2001	Antonsson et al.			
Т	23.	6,265,397	July 24, 2001	Karlsson et al.			
Т	24.	6,337,346	January 8, 2002	Gustafsson et al.			
Т	25.	6,337,394	January 8, 2002	Karlsson et al.			
Т	26.	6,433,186	August 13, 2002	Inghardt et al.			
Т	27.	6,440,937	August 27, 2002	Baucke et al.			
Т	28.	6,440,939	August 27, 2002	Edvardsson et al.			
Т	29.	6,444,817	September 3, 2002	Bohm et al.			
	30.	6,455,671	September 24, 2002	Bohm et al.			
	31.	6,479,078	November 12, 2002	Hedstrom et al.			
	32.	6,521,253	February 18, 2003	Forsman et al.			
	33.	6,576,657	June 10, 2003	Karlsson et al.	I		
V	34.	6,576,245	June 10, 2003	Lundgren et al.			
/NI	C /35.	6,599,894	July 29, 2003	Inghardt et al.			

FOREIGN PATENT DOCUMENTS

Document No. Date Country Class Sub-Class Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Nizal Chandrakumar/ Date Considered

06/10/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### Attorney Docket No. Application No. INFORMATION DISCLOSURE CITATION 056291-5273 10/516.423 (Use several sheets if necessary) Applicants: Susanna A. Alami et al. PTO Form 1449 May 9, 2007 Filing Date: July 25, 2005 Group Art Unit: 1615 U.S. PATENT DOCUMENTS Initial Document No. Class Sub-Class Date Name Filing Date N.C. 36 6.617.320 September 9, 2003 Gustafsson et al 6.660.279 December 9, 2003 Lundgren et al. 6.716.834 April 6, 2004 38 Andersson et al. 6,750,243 39 June 15, 2004 Inghardt et al. 40 6,838,478 January 4, 2005 Gustafsson et al. 41. 6,875,446 April 5, 2005 Forsman et al. 42. 6,888,007 May 3, 2005 Edvardsson et al. 43. 6,921,758 July 26, 2005 Gustafsson et al. 44 6.984.627 January 10, 2006 Antonsson et al. 45. 6,998,136 February 14, 2006 Lundgren et al. 46 7.056,907 June 6, 2006 Inghardt et al. 47 7,129,233 October 31, 2006 Inghardt et al. 48 20040019033 January 29, 2004 Inghardt et al. 49. 20040242492 December 2, 2004 Inghardt et al. FOREIGN PATENT DOCUMENTS Document No. Date Country Class Sub-Class Translation I/N.C./ 50. EP 0185390 October 2, 1991 Europe Claims 51 EP 0195212 November 24 1993 Europe 52. FP 0293881 March 10, 1993 Europe EP 0362002 July 26, 1995 Europe 54 FP 0364344 May 6, 1998 Europe 55 EP 0468231 September 21, 1994 Europe Claims 56 EP 0526877 February 10, 1993 Europe 57 March 3, 1993 Europe 58 EP 0539059 April 28, 1993 Europe 59. EP 0542525 July 8, 1998 Europe 60. FP 0559046 July 11, 2001 Europe Claims 61. EP 0641779 March 8, 1995 Europe US 5,559,232 62 EP 0648780 April 19, 1995 Europe 63. EP 0669317 September 4, 2002 Europe 64 FP 0672658 September 17, 2003 Europe 65. EP 0686642 December 13, 1995 Europe 66. EP 0773955 April 16, 2003 Europe Claims 67 JP 57149217 September 14, 1982 Abstract Japan 68 WO 93/11152 June 10, 1993 WIPO 69 WO 93/18060 September 16, 1993 WIPO 70 WO 94/29269 December 22, 1994 WIPO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009

December 22, 1994

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

WIPO

71.

WO 94/29336

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449 May 9, 2007

Attorney Docket No.	Application No.
056291-5273	10/516,423

Applicants: Susanne A. Alami et al.

Filing Date: July 25, 2005 Group Art Unit: 1615

	Document No.	Date	Country	Class	Sub-Class	Translation
/N C7/2.	WO 95/23609	September 8, 1995	WIPO			
73.	WO 95/35309	December 28, 1995	WIPO		1	US 6,455,671
74.	WO 96/03374	February 8, 1996	WIPO			
75.	WO 96/25426	August 22, 1996	WIPO			US 6,444,817
		0 , ,				US 6,030,972
76.	WO 96/26717	September 6, 1996	WIPO			
77.	WO 96/31504	October 10, 1996	WIPO			
78.	WO 96/32110	October 17, 1996	WIPO			
79.	WO 97/02284	January 23, 1997	WIPO			
80.	WO 97/23499	July 3, 1997	WIPO			
81.	WO 97/39770	October 30, 1997	WIPO			
82.	WO 97/46577	December 11, 1997	WIPO	1		
83.	WO 97/49404	December 31, 1997	WIPO			
84.	WO 98/01422	January 15, 1998	WIPO			
85.	WO 98/06740	February 19, 1998	WIPO			US 6,440,937
86.	WO 98/16252	April 23, 1998	WIPO			
87.	WO 98/57932	December 23, 1998	WIPO			
88.	WO 99/21586	May 6, 1999	WIPO			
89.	WO 99/29305	June 17, 1999	WIPO			
90.	WO 99/29664	June 17, 1999	WIPO			
91.	WO 99/39698	August 12, 1999	WIPO			
92.	WO 00/12043	March 9, 2000	WIPO			
93.	WO 00/13671	March 16, 2000	WIPO			
94.	WO 00/13710	March 16, 2000	WIPO			
95.	WO 00/14110	March 16, 2000	WIPO			
96.	WO 00/35869	June 22, 2000	WIPO			
97.	WO 00/42059	July 20, 2000	WIPO			
96.	WO 01/02426	January 11, 2001	WIPO			
99.	WO 01/87879	November 22, 2001	WIPO			
100.	WO 02/14270	February 21, 2002	WIPO			
101.	WO 02/19990	March 14, 2002	WIPO			
102.	WO 02/44145	June 6, 2002	WIPO			
103.	WO 03/000293	January 3, 2003	WIPO		<del>                                     </del>	
104.	WO 03/018551	March 06, 2003	WIPO			
105.	WO 03/101423	December 11, 2003	WIPO	_		
106.	WO 03/101424	December 11, 2003	WIPO			
/N.C./ 107.	WO 03/101957	December 11, 2003	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/N.C./108. Baveja et al. "Zero-order release hydrophilic matrix tablets of beta-adrenergic blockers" International Journal of Pharmaceutics 39:39-45 (1987)

109. Bonferoni et al. "On the employment of lambda-carrageenan in a matrix system. II. Lambda-Carrageenan and hydroxypropylmethylcellulose mixtures" J. Controlled Release 30:175-182 (1994)

Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary) PTO Form 1449 May 9, 2007    Filing Date: July 25, 2005   Group Art Unit: 1615	INFORMATION DISCLOSURE CITATION		056291-5273			10/516,423			
PTO Form 1449 May 9, 2007  Filing Date: July 25, 2005  Group Art Unit: 1615  U.S. PATENT DOCUMENTS  Initial  Document No.  Date  Name  Class  Sub-Class  Filing Date  FOREIGN PATENT DOCUMENTS  Document No.  Date  Country  Class  Sub-Class  Translation  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110.  Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  Ham-Yong Park et al. "Effect of Ph on Drug Release From Pobysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talkdar et al. "in vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" international Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 19776-70-2 December 1994  V. 115. CAS RN 19776-70-70 2 December 1994  V. 116. CAS RN 30318-53-4 November 2000  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in	PTO Form 1449			Applicants: Susanna A. Alami et al.					
Initial Document No. Date Name Class Sub-Class Filing Date  FOREIGN PATENT DOCUMENTS  Document No. Date Country Class Sub-Class Translation  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C./ 110. Berge et al. "Pharmaceutical Salts" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" international Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 193776-70-2 December 1994  115. CAS RN 1939776-70-2 December 1994  116. CAS RN 30318-53-4 November 2000  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in							Grow	a Art I Init: 1615	
FOREIGN PATENT DOCUMENTS    Document No.   Date   Country   Class   Sub-Class   Translation			Way 9, 2007				15	Grou	AR Onit: 1015
FOREIGN PATENT DOCUMENTS    Document No.   Date   Country   Class   Sub-Class   Translation	Initial		Document No.				Close	Sub Class	Filing Data
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of Pd no Trug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 192939-72-3 August 1997  N.C. 116. CAS RN 30318-53-4 November 2000  Date Considered 06/10/2009  Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in	initiai		Document 140.	Date		vanic	Ciass	Sub-Class	rinig Date
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of Pd no Trug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 192939-72-3 August 1997  N.C. 116. CAS RN 30318-53-4 November 2000  Date Considered 06/10/2009  Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of Pd no Trug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 192939-72-3 August 1997  N.C. 116. CAS RN 30318-53-4 November 2000  Date Considered 06/10/2009  Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of Pd no Trug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 192939-72-3 August 1997  N.C. 116. CAS RN 30318-53-4 November 2000  Date Considered 06/10/2009  Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  N.C. 110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)  111. Ham-Yong Park et al. "Effect of Pd no Trug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)  112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)  113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)  114. CAS RN 192939-72-3 August 1997  N.C. 116. CAS RN 30318-53-4 November 2000  Date Considered 06/10/2009  Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in		1		FOREIGN	PATENT DO	CUMENTS			
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000			Document No.				Class	Sub-Class	Translation
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000									
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000									
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000		-			1				
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000									
N.C.   110. Berge et al. "Pharmaceutical Salis" J. of Pharmaceutical Sciences 66(1): 1-19 (1977)   111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998)   112. Picker "The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets"   European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999)   113. Tallukdar et al. "in vivo evaluation of xanthang um as a potential excipient for oral controlled-release matrix tablet formulation" International Journal of Pharmaceutics 169(1):105-113 (1998)   114. CAS RN 19776-70-2 December 1994   115. CAS RN 192939-72-3 August 1997   116. CAS RN 30318-53-4 November 2000   116. CAS RN 30318-53-4 November 2000   117. CAS RN 30318-53-4 November 2000   118. CAS RN 30318-53-4 November 2000			OTHER DO	OCUMENTS (Included	dina Authon T	ida Data Baut	inant Da	roc oto)	
111. Ham-Yong Park et al. "Effect of pH on Drug Release From Polysaccharide Tablets" Drug Delivery 5:13-18 (1998) 112. Picker "The use of carrageana in mixture with microcrystalline cellulose and its functionality for making tablets" European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999) 113. Talukdar et al. "In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation" international Journal of Pharmaceutics 169(1):105-113 (1998) 114. CAS RN 159776-70-2 December 1994 115. CAS RN 15939-72-3 August 1997    N.C./   116. CAS RN 30318-53-4 November 2000	- /N.C.	110							
Examiner /Nizal Chandrakumar/   Date Considered   06/10/2009	//\	111.	Ham-Yong Park et al.	"Effect of pH on Dru	ig Release Fron	Polysaccharid	e Tablets	' Drug Deliv	ery 5:13-18 (1998)
International Journal of Pharmaceutics 169(1):105-113 (1998)			European J Pharmaceu	itics and Biopharmac	eutics 48(1):27	-36 (1999)			•
115. CAS RN 192939-72-3 August 1997  116. CAS RN 30318-53-4 November 2000   Examiner /Nizal Chandrakumar/   Date Considered   06/10/2009    Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in			formulation" Internation	onal Journal of Pharn				controlled-re	elease matrix tablet
Examiner  //Nizal Chandrakumar/  Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in	V								
Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in	*/N.C./	110.	CAS KN 30316-33-41	November 2000					
Examiner /Nizal Chandrakumar/ Date Considered 06/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in		-							
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in		<u> </u>							
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in				-					
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in	-	_							
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
/NIZAI GRANGIAKUITIAI/ 00/10/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
	Examiner	/Niz	ı al Chandrakumar/	Date (	Considered	06/10/200	9		
								draw line th	rough citation if not in